» Authors » Colin G Stott

Colin G Stott

Explore the profile of Colin G Stott including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 532
Followers 0
Related Specialty
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gray R, Stott C, Jones N, Di Marzo V, Whalley B
Cannabis Cannabinoid Res . 2020 Jul; 5(2):145-149. PMID: 32656346
Highly purified cannabidiol (CBD) (approved as Epidiolex in the United States) has demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut or Dravet syndrome in four randomized controlled...
2.
Sellers E, Schoedel K, Bartlett C, Romach M, Russo E, Stott C, et al.
Clin Pharmacol Drug Dev . 2016 Apr; 2(3):285-94. PMID: 27121791
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray has proved efficacious in the treatment of spasticity in multiple sclerosis and chronic pain. A thorough QT/QTc study was performed to investigate the effects of...
3.
De Petrocellis L, Ligresti A, Moriello A, Iappelli M, Verde R, Stott C, et al.
Br J Pharmacol . 2012 May; 168(1):79-102. PMID: 22594963
Background And Purpose: Cannabinoid receptor activation induces prostate carcinoma cell (PCC) apoptosis, but cannabinoids other than Δ(9) -tetrahydrocannabinol (THC), which lack potency at cannabinoid receptors, have not been investigated. Some...
4.
De Petrocellis L, Ligresti A, Moriello A, Allara M, Bisogno T, Petrosino S, et al.
Br J Pharmacol . 2010 Dec; 163(7):1479-94. PMID: 21175579
Background And Purpose: Cannabidiol (CBD) and Δ(9) -tetrahydrocannabinol (THC) interact with transient receptor potential (TRP) channels and enzymes of the endocannabinoid system. Experimental Approach: The effects of 11 pure cannabinoids...